IDH2 and glioblastoma: Given the role of MGMT promoter methylation as predictive biomarker for TMZ response in glioblastoma IDH-wt, we compared the patient’s outcome for tumors with and without MGMT promoter methylation but did not find a difference (Supplementary Fig. 3a, online resource).